Theranexus publishes its financial results for the first half of 2025

On September 25, 2025, Theranexus, a biopharmaceutical company focused on rare neurological diseases, announced its half-year results as of June 30, 2025. The company continued its cost-cutting efforts, resulting in a nearly 20% decrease in operating expenses compared to the previous year.

Other purchases and expenses fell by 19%, and labor costs by 20%. Nevertheless, the half-year ended with a loss of €1,072,000 despite operating subsidies and a research tax credit. Available cash flow almost doubled, reaching €2,124,000.

The reductions are due to the completion of a clinical trial and a reduction in staffing levels. Theranexus remains committed to its key projects, such as TX01 and Batten-1, in collaboration with Exeltis.